VSIR and lymphoma: In a xenograft NCG model of CD19+ CA-46 lymphoma, CD19–CAR-T cells with shRNA-mediated ablation of PD-1H significantly improved the antitumor activity of the CAR-T cells to inhibit the lymphoma growth and prolonged the survival of tumor-bearing mice.